Tumor escape from immunoprotection studied in a murine model of myeloma minimal residual disease (MRD)
- Prosjektnummer
- 2013076
- Ansvarlig person
- Bjarne Bogen
- Institusjon
- Oslo universitetssykehus HF
- Prosjektkategori
- Postdoktorstipend
- Helsekategori
- Cancer, Inflammatory and Immune System
- Forskningsaktivitet
- 1. Underpinning
Tumors Escape CD4+ T-cell-Mediated Immunosurveillance by Impairing the Ability of Infiltrating Macrophages to Indirectly Present Tumor Antigens.
Cancer Res 2015 Aug 15;75(16):3268-78. Epub 2015 jun 2
PMID: 26038231
Idiotype-specific CD4(+) T cells eradicate disseminated myeloma.
Leukemia 2016 May;30(5):1216-20. Epub 2015 okt 9
PMID: 26449664
Indirect CD4+ T-cell-mediated elimination of MHC II(NEG) tumor cells is spatially restricted and fails to prevent escape of antigen-negative cells.
Eur J Immunol 2014 Sep;44(9):2625-37. Epub 2014 jun 20
PMID: 24846412
How Do CD4(+) T Cells Detect and Eliminate Tumor Cells That Either Lack or Express MHC Class II Molecules?
Front Immunol 2014;5():174. Epub 2014 apr 15
PMID: 24782871
Naive idiotope-specific B and T cells collaborate efficiently in the absence of dendritic cells.
J Immunol 2014 May 1;192(9):4174-83. Epub 2014 apr 4
PMID: 24706724
Molecular profiling of tumor-specific TH1 cells activated in vivo.
Oncoimmunology 2013 May 1;2(5):e24383.
PMID: 23762808
- Ole Audun Haabeth Postdoktorstipendiat
- Bjarne Bogen Forskningsgruppeleder
eRapport er utarbeidet av Sølvi Lerfald og Reidar Thorstensen, Regionalt kompetansesenter for klinisk forskning, Helse Vest RHF, og videreutvikles av de fire RHF-ene i fellesskap, med støtte fra Helse Vest IKT
Alle henvendelser rettes til eRapport